# Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer

> **NCT03691311** · EARLY_PHASE1 · UNKNOWN · sponsor: **Institut Català d'Oncologia** · enrollment: 60 (estimated)

## Conditions studied

- Breast Neoplasm Female
- Stage I Breast Cancer
- Stage II Breast Cancer
- Hormone Receptor Negative Neoplasm
- Hormone Receptor Positive Tumor

## Interventions

- **DRUG:** Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

## Key facts

- **NCT ID:** NCT03691311
- **Lead sponsor:** Institut Català d'Oncologia
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-05
- **Primary completion:** 2022-07-05
- **Final completion:** 2023-02-05
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03691311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03691311, "Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03691311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*